March 25, 2025 10:57 AM EDT
R&D

Kezar toplines small Phase 2a dataset in au­toim­mune liv­er dis­ease

Max Gelman

Senior Editor

Kezar re­port­ed new da­ta Tues­day morn­ing from a small Phase 2a study in au­toim­mune he­pati­tis, or AIH, a con­di­tion where the im­mune sys­tem at­tacks the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sen­ate con­firms Makary as FDA chief with agency cuts, re­turn-to-of­fice in force

Lyn­dra Ther­a­peu­tics to wind down amid fund­ing hur­dles for long-act­ing drug tech­nol­o­gy

Trump tar­iffs would in­crease costs for al­most every bio­phar­ma com­pa­ny, sur­vey claims

WuXi Bi­o­log­ics’ li­cens­ing deals help off­set Biose­cure threat in the US

Mer­ck strikes deal for heart drug, worth up to $2B, with Chi­na’s Hen­grui

Covid con­trar­i­an Bhat­tacharya is con­firmed as NIH chief, tak­ing over at a fraught mo­ment for fed­er­al re­search

A service from the Financial Times